Skip to main content
SpringerLink
Log in

Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves’ orbitopathy?

  • Comment
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bartalena L, Fatourechi V (2014) Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 37:691–700

    Article  PubMed  CAS  Google Scholar 

  2. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, on behalf of the European Group on Graves’ Orbitopathy (EUGOGO) (2016) The 2016 European Thyroid Association/European group on Graves’ orbitopathy Guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 5:9–26

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Prummel MF, Mourits P, Berghout A, Krenning EP, van der Gaag R, Koornneef L, Wiersinga WM (1989) Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med 321:1353–1359

    Article  PubMed  CAS  Google Scholar 

  4. Tanda ML, Bartalena L (2012) Efficacy and safety of orbital radiotherapy for Graves’ orbitopathy. J Clin Endocrinol Metab 97:3857–3865

    Article  PubMed  CAS  Google Scholar 

  5. Kahaly GJ, Riedl M, Konig J, Pitz S, Ponto K, Diana T, Kampmann E, Kolbe E, Eckstein A, Moeller LC, Fuhrer D, Salvi M, Currò N, Campi I, Covelli D, Leo M, Marinò M, Menconi F, Marcocci C, Bartalena L, Perros P, Wiersinga WM, for the European Group on Graves’ Orbitopathy (EUGOGO) (2018) Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomized, observer-masked, multicentre study. Lancet Diabetes Endocrinol 6:287–298

    Article  PubMed  CAS  Google Scholar 

  6. Rajendram R, Taylor PN, Wilson VJ, Harris N, Morris OC, Tomlinson M, Yarrow S, Garrott H, Herbert HM, Dick AD, Cook A, Gattamaneni R, Jain R, Olver J, Hurel SJ, Bremner F, Drummond SR, Kemp E, Ritchie BM, RumsEy N, Morris D, Lane C, Palanappian N, Li C, Pell J, Hills R, Ezra DG, Potts MJ, Jackson S, Rose GE, Plowman N, Bunce C, Uddin JM, Lee RWJ, Dayan CM (2018) Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomized controlled trial. Lancet Diabetes Endocrinol 6:299–309

    Article  PubMed  Google Scholar 

  7. Sipkova Z, Insull EA, David J, Turner HE, Karen S, Norris JH (2018) Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach. Clin Endocrinol 89:834–839

    Article  CAS  Google Scholar 

  8. Piantanida E, Bartalena L (2017) Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest 40:885–887

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrine Unit, ASST dei Sette Laghi, Department of Medicine and Surgery, University of Insubria, Viale Borri, 57, 21100, Varese, Italy

    M. L. Tanda, E. Piantanida, E. Masiello, C. Cusini & L. Bartalena

Authors
  1. M. L. Tanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Piantanida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Masiello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Cusini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Bartalena
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Bartalena.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

This paper did not involve patients.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tanda, M.L., Piantanida, E., Masiello, E. et al. Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves’ orbitopathy?. J Endocrinol Invest 42, 351–352 (2019). https://doi.org/10.1007/s40618-019-01015-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-019-01015-8

Keywords

Search

Navigation